| 产品编号 | bs-8512R |
| 英文名称 | MSX1 Rabbit pAb |
| 中文名称 | MSH同源蛋白1样蛋白抗体 |
| 别 名 | Msh homeobox 1 like protein; Homeobox 7; Homeobox protein Hox-7; Homeobox protein MSX 1; Homeobox protein MSX-1; Homeobox protein MSX1; Homeobox, msh like 1; Homeobox, msh-like 1; HOX 7; Hox 7.1; Hox-7; HOX7; Hox7.1; HYD 1; HYD1; msh(Drosophila) homeo box homolog 1(formerly homeo box 7); Msh; msh homeo box 1; msh homeo box homolog 1; Msh homeobox 1; Msh homeobox 1-like protein; msh homeobox homolog 1(Drosophila); msh homeobox homolog 1; MSH, Drosophila, Homolog of, 1; MSX 1; MSX1; MSX1_HUMAN; Muscle segment homeobox; Muscle segment homeobox, Drosophila, Homolog of, 1; OFC5; STHAG1. |
 |
Specific References (2) | bs-8512R has been referenced in 2 publications.
[IF=3.337] Linlin Yang. et al. Identification and Validation of MSX1 as a Key Candidate for Progestin Resistance in Endometrial Cancer. Oncotargets Ther. 2020; 13: 11669–11688 WB ; Human.
[IF=1.85] Mu, Hailong, et al. "The function of Msx1 gene in promoting meiosis of dairy goat male germline stem cells (mGSCs)." Cell Biochemistry and Function (2013). Goat.
|
| 研究领域 | 细胞生物 免疫学 神经生物学 信号转导 干细胞 |
| 抗体来源 | Rabbit |
| 克隆类型 | Polyclonal |
| 交叉反应 | Human,Mouse (predicted: Rat,Cow,Dog) |
| 产品应用 | WB=1:500-2000,IHC-P=1:100-500,IHC-F=1:100-500,IF=1:50-200,Flow-Cyt=5μg /Test
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理论分子量 | 31 kDa |
| 检测分子量 | |
| 细胞定位 | 细胞核 |
| 性 状 | Liquid |
| 浓 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human MSX1: 151-297/297 |
| 亚 型 | IgG |
| 纯化方法 | affinity purified by Protein A |
| 缓 冲 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存条件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事项 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 产品介绍 |
Acts as a transcriptional repressor. May play a role in limb-pattern formation. Acts in cranofacial development and specifically in odontogenesis. Expression in the developing nail bed mesenchyme is important for nail plate thickness and integrity. Function: Acts as a transcriptional repressor. May play a role in limb-pattern formation. Acts in cranofacial development and specifically in odontogenesis. Expression in the developing nail bed mesenchyme is important for nail plate thickness and integrity. Subcellular Location: Nucleus Tissue Specificity: Expressed in the developing nail bed mesenchyme. Post-translational modifications: Sumoylated by PIAS1, desumoylated by SENP1 (By similarity). DISEASE: Defects in MSX1 are the cause of tooth agenesis selective type 1 (STHAG1) [MIM:106600]. A form of selective tooth agenesis, a common anomaly characterized by the congenital absence of one or more teeth. Selective tooth agenesis without associated systemic disorders has sometimes been divided into 2 types: oligodontia, defined as agenesis of 6 or more permanent teeth, and hypodontia, defined as agenesis of less than 6 teeth. The number in both cases does not include absence of third molars (wisdom teeth). Tooth agenesis selective type 1 can be associated with orofacial cleft in some patients. Note=MSX1 is deleted in some patients with Wolf-Hirschhorn syndrome (WHS). WHS results from sub-telomeric deletions in the short arm of chromosome 4. Defects in MSX1 are the cause of Witkop syndrome (WITS) [MIM:189500]. WITS is a form of ectodermal dyslasia also called tooth-and-nail syndrome or dysplasia of nails with hypodontia. Ectodermal dysplasias (EDs) constitute a heterogeneous group of developmental disorders affecting tissues of ectodermal origin. EDs are characterized by abnormal development of two or more ectodermal structures such as hair, teeth, nails and sweat glands, with or without any additional clinical sign. Each combination of clinical features represents a different type of ectodermal dysplasia. Witkop syndrome is characterized by abnormalities largely limited largely to teeth (some of which are missing) and nails (which are poorly formed early in life, especially toenails). This condition is distinguished from anhidrotic ectodermal dysplasia by autosomal dominant inheritance and little involvement of hair and sweat glands. The teeth are not as severely affected. Defects in MSX1 are the cause of non-syndromic orofacial cleft type 5 (OFC5) [MIM:608874]; also called non-syndromic cleft lip with or without cleft palate 5. Non-syndromic orofacial cleft is a common birth defect consisting of cleft lips with or without cleft palate. Cleft lips are associated with cleft palate in two-third of cases. A cleft lip can occur on one or both sides and range in severity from a simple notch in the upper lip to a complete opening in the lip extending into the floor of the nostril and involving the upper gum. Similarity: Belongs to the Msh homeobox family. Contains 1 homeobox DNA-binding domain. SWISS: P28360 Gene ID: 4487 Database links: Entrez Gene: 4487 Human Entrez Gene: 17701 Mouse Entrez Gene: 692067 Rhesus monkey Omim: 142983 Human SwissProt: Q2VL88 Chimpanzee SwissProt: P28360 Human SwissProt: P13297 Mouse SwissProt: Q2VL87 Rhesus monkey Unigene: 424414 Human Unigene: 256509 Mouse Unigene: 18117 Rat |
| 产品图片 |
Sample:
Utreus (Mouse) Lysate at 40 ug
Hela Cell (Human) Lysate at 40 ug
Siha Cell (Human) Lysate at 40 ug
A673 Cell (Human) Lysate at 40 ug
Primary: Anti- MSX1 (bs-8512R) at 1/300 dilution
Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
P
Tissue/cell: mouse embryo tissue; 4% Paraformaldehyde-fixed and paraffin-embedded;
Antigen retrieval: citrate buffer ( 0.01M, pH 6.0 ), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat
Positive control: Hela cells
Concebtration: 5μg/10^6 cells
Incubation conditions: Avoid light , 30 minutes on the ice.
|
| 1、抗体溶解方法 | |
| 2、抗体修复方式 | |
| 3、常用试剂的配制 | |
| 4、免疫组化操作步骤 | |
| 5、免疫组化问题解答 | |
| 6、Western Blotting 操作步骤 | |
| 7、Western Blotting 问题解答 | |
| 8、关于肽链的设计 | |
| 9、多肽的溶解与保存 | |
| 10、酶标抗体效价测定程序 | |
